Mackenzie Financial Corp Purchases 13,240 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Mackenzie Financial Corp lifted its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIXGet Rating) by 44.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 43,136 shares of the company’s stock after acquiring an additional 13,240 shares during the period. Mackenzie Financial Corp’s holdings in Neurocrine Biosciences were worth $4,205,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in NBIX. Polar Capital Holdings Plc increased its position in shares of Neurocrine Biosciences by 2,114.5% during the first quarter. Polar Capital Holdings Plc now owns 759,287 shares of the company’s stock valued at $71,183,000 after acquiring an additional 725,000 shares in the last quarter. American Century Companies Inc. boosted its holdings in Neurocrine Biosciences by 534.5% in the first quarter. American Century Companies Inc. now owns 795,848 shares of the company’s stock worth $74,611,000 after purchasing an additional 670,415 shares during the last quarter. Wellington Management Group LLP purchased a new stake in Neurocrine Biosciences in the first quarter worth approximately $36,508,000. Pictet Asset Management SA boosted its holdings in Neurocrine Biosciences by 38.2% in the second quarter. Pictet Asset Management SA now owns 1,071,797 shares of the company’s stock worth $104,479,000 after purchasing an additional 296,422 shares during the last quarter. Finally, Deerfield Management Company L.P. Series C boosted its holdings in Neurocrine Biosciences by 20.3% in the first quarter. Deerfield Management Company L.P. Series C now owns 1,657,800 shares of the company’s stock worth $155,419,000 after purchasing an additional 279,855 shares during the last quarter. Institutional investors own 93.18% of the company’s stock.

Wall Street Analysts Forecast Growth

NBIX has been the topic of several research reports. Morgan Stanley raised their target price on shares of Neurocrine Biosciences from $102.00 to $120.00 and gave the stock an “equal weight” rating in a report on Wednesday, November 2nd. JPMorgan Chase & Co. raised their target price on shares of Neurocrine Biosciences from $138.00 to $143.00 and gave the stock an “overweight” rating in a report on Thursday, November 3rd. Barclays lifted their price target on shares of Neurocrine Biosciences from $110.00 to $113.00 and gave the stock an “overweight” rating in a research note on Friday, August 5th. BMO Capital Markets lifted their price target on shares of Neurocrine Biosciences from $78.00 to $101.00 in a research note on Wednesday, November 2nd. Finally, TheStreet upgraded shares of Neurocrine Biosciences from a “c+” rating to a “b” rating in a research note on Tuesday, November 1st. Seven investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $124.00.

Neurocrine Biosciences Stock Up 4.4 %

Neurocrine Biosciences stock opened at $120.16 on Monday. The company’s 50-day moving average price is $111.42 and its 200-day moving average price is $101.52. Neurocrine Biosciences, Inc. has a twelve month low of $71.88 and a twelve month high of $125.99. The company has a market cap of $11.55 billion, a PE ratio of 210.81 and a beta of 0.52.

Insider Buying and Selling

In related news, insider Eric Benevich sold 24,593 shares of Neurocrine Biosciences stock in a transaction dated Tuesday, November 8th. The shares were sold at an average price of $125.33, for a total transaction of $3,082,240.69. Following the completion of the transaction, the insider now directly owns 15,643 shares of the company’s stock, valued at approximately $1,960,537.19. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other Neurocrine Biosciences news, insider Darin Lippoldt sold 4,518 shares of the business’s stock in a transaction dated Thursday, November 3rd. The shares were sold at an average price of $125.02, for a total value of $564,840.36. Following the completion of the sale, the insider now directly owns 29,234 shares of the company’s stock, valued at approximately $3,654,834.68. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Eric Benevich sold 24,593 shares of the business’s stock in a transaction dated Tuesday, November 8th. The shares were sold at an average price of $125.33, for a total transaction of $3,082,240.69. Following the completion of the sale, the insider now directly owns 15,643 shares of the company’s stock, valued at $1,960,537.19. The disclosure for this sale can be found here. In the last ninety days, insiders sold 70,531 shares of company stock valued at $8,403,796. Company insiders own 4.40% of the company’s stock.

Neurocrine Biosciences Company Profile

(Get Rating)

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas.

Featured Stories

Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIXGet Rating).

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.